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increasing severity of Tr has been associated 
with substantial morbidity and mortality: up to 
one third of patients with severe Tr die within 
one year of diagnosis.1 avoiding TV repair in 
less than severe secondary Tr has been toler-
ated for a long time, following the mislead-
ing belief that functional Tr would reduce or 
even disappear once the left-sided pathology 
had been resolved. However, half of all pa-
tients with untreated Tr developed progres-
sive valve dysfunction, despite successful left-
sided surgery, entailing a poor prognosis.1, 3, 4 
The increased understanding of the long-term 
adverse consequences of severe Tr, coupled 
with continued advances in surgical and per-
cutaneous techniques, is currently leading to a 
more aggressive treatment strategy. The euro-
pean guidelines recommend TV repair during 
left-heart surgery in the presence of severe Tr 
(class i; level of evidence C), moderate prima-
ry TR (IIa; C), and ≥mild TR with annular dila-
tation (≥40 mm) (IIa; C). Surgical repair is also 
recommended in symptomatic patients with 
severe primary Tr (i; C) or in asymptomatic 
patients with progressive rV dilatation (iia; 
C).5 There is general recognition, however, 
that the evidence underlying current guideline 
recommendations for management of patients 
The assessment and management of tri-cuspid valve (TV) disease have evolved 
substantially during the past several years. 
The increased understanding of the long-term 
adverse consequences of severe tricuspid re-
gurgitation (Tr), along with the continued 
advances in surgical and percutaneous tech-
niques, has led to a renewed interest in the 
“forgotten valve”.1, 2
in this special monographic issue of Minerva 
Cardioangiologica, entitled “Functional tricus-
pid regurgitation: from pathophysiology to the 
novel percutaneous approaches”, we will have 
the privilege of outstanding state-of-the-art 
contributions, directly provided from the best 
worldwide experts of this challenging topic.
The TV disorders have traditionally been ac-
corded lesser importance than that of the left-
sided valvular heart disease. rarely Tr may be 
ascribed to a primary valve lesion; more fre-
quently, a morphologically normal valve with 
annular dilatation and/or leaflet tethering due 
to right ventricular (rV) overload is encoun-
tered, the so-called “functional Tr”. 
This is commonly consequence of a heart 
valve disease of the left-side, atrial fibrillation 
or pulmonary hypertension.2 While trivial Tr 
is frequently encountered in normal subjects, 
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safety with the novel transcatheter devices.12
In conclusion, continued refinement of 
transcatheter techniques offers hope for less 
invasive means to treat severe Tr in many 
patients deemed at prohibitive or high surgi-
cal risk. This special issue on functional Tr 
contributes and shapes the future of TV inter-
ventions, defining the complementary role of 
medical, transcatheter and surgical therapies.
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with TV disease does not include any suffi-
ciently rigorous randomized controlled trials 
to guide the clinical practice.5, 6
in this monographic issue, entirely dedicat-
ed to functional TR, the first contribution is by 
Patrick O’Gara from the Boston Harvard Med-
ical School and Brigham and Women’s Hos-
pital, discussing in greater detail the TV com-
plex anatomy, the epidemiology of TV disease 
and the increasing evidence that functional Tr 
is prognostically significant, warranting inter-
vention. The appropriate patient selection for 
intervention along with the proper timing will 
also be addressed.7
Rebecca Hahn from the Columbia Univer-
sity and New York-Presbyterian Hospital will 
introduce the readers to a controversial and 
challenging topic, the echocardiographic cri-
teria relevant to assess functional Tr sever-
ity and the pre-procedural degree of rV (dys)
function.8
Ottavio Alfieri et al. from the San Raffaele 
University Hospital of Milan, will report the 
techniques, the acute and long-term outcomes 
provided by TV surgery, addressing the evi-
dences in favor of a more aggressive surgical 
approach to functional Tr.9
The clinical need forecasting transcatheter 
tricuspid therapies and the Heart Team ap-
proach to assess patients’ operability will be 
analyzed by Alec Vahanian, from the Bichat 
University Hospital, Paris.10
another fundamental aspect of the monog-
raphy relies on the preliminary experiences of 
transcatheter treatments for functional Tr in 
symptomatic inoperable patients, which are 
discussed by Josep rodés-Cabau et al. from 
the Quebec Heart & lung institute and laval 
University, Canada.11
The last original contribution, by Jeroen 
Bax et al. from the University Medical Center 
Leiden, will bring to the readers’ attention the 
pivotal role played by multimodality imaging 
techniques in achieving procedural success and 
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